In Vitro Diagnostics (POC/Rapid diagnostics) Global market - Forecast to 2020
In vitro diagnostics are tests that diagnose and prevent diseases, conditions or infections. IVD tests are performed outside body in an artificial environment on samples such as blood, urine, tissue isolated from human body. IVD is classified into 3 types namely: clinical laboratory testing, near-patient testing, self-testing. IVD market is segmented by-techniques (including immunoassays, point of care, molecular diagnostics, hematology, coagulation, microbiology, clinical techniques, microbiology), product-type (including instruments, reagents, services, data management systems), usability (including disposable, reusable), applications (including diabetes, oncology, cardiology, HIV/AIDS, autoimmune disease, nephrology, drug testing), -end-user (including hospitals, laboratories, academics) and geography (globally).
The global IVD market was reported with high revenue in previous years and hence expected to grow at a high CAGR by 2019. The Asia-Pacific and RoW regions are expected to register a significant growth rate for the IVD market. North America commands the largest share while Asia Pacific is the fastest revenue growing region.
IVD market growth is driven by factors such as increase in incidences of chronic and infectious diseases across all age cohorts, genetic diseases, aging population, rising acceptance of personalized medicine, rise in healthcare awareness in patients and high unmet medical needs in diagnosing diseases. Screening initiatives and high investment in healthcare infrastructures mainly contributes to market growth. Whereas, difficulty in rendering rapid diagnostic results, stringent regulatory policies, reimbursement issues and economic crisis are the major growth restraints. Different geographies is an opportunistic factor which improved IVD market growth.
Roche diagnostics (Basel, Switzerland) is expected to be the largest player in the IVD market, followed by Siemens and Abbott. The IVD market is highly consolidated, with the major players holding close to 80% market share. Top ten major players are Roche Diagnostics, Siemens Healthcare(Erlangen, Germany), Abbott(Abbott Park, Illinois), Johnson and Johnson(New Jersey), Beckman Coulter(Massachusetts), Becton Dickinson(U.S.), bioMerieux (France), Bayer Diabetes(Germany), Sysmex (U.S.) and Bio-Rad(California). Key players such as Thermo Fisher Scientific, Inc., QIAGEN N.V., and ARKRAY, Inc. have established new manufacturing facilities and R&D units in China to grow IVD market.
The focus of this research report description was on various levels of analysis, industry, market shares, value chain, PESTEL analysis and company profiles which together comprise and augment about competitive landscape, emerging and high growth segments of in vitro diagnostic (molecular diagnostics & point of care testing), emerging technologies.
The report provides an in depth market analysis of the above mentioned segments across the following regions:
The global IVD market was reported with high revenue in previous years and hence expected to grow at a high CAGR by 2019. The Asia-Pacific and RoW regions are expected to register a significant growth rate for the IVD market. North America commands the largest share while Asia Pacific is the fastest revenue growing region.
IVD market growth is driven by factors such as increase in incidences of chronic and infectious diseases across all age cohorts, genetic diseases, aging population, rising acceptance of personalized medicine, rise in healthcare awareness in patients and high unmet medical needs in diagnosing diseases. Screening initiatives and high investment in healthcare infrastructures mainly contributes to market growth. Whereas, difficulty in rendering rapid diagnostic results, stringent regulatory policies, reimbursement issues and economic crisis are the major growth restraints. Different geographies is an opportunistic factor which improved IVD market growth.
Roche diagnostics (Basel, Switzerland) is expected to be the largest player in the IVD market, followed by Siemens and Abbott. The IVD market is highly consolidated, with the major players holding close to 80% market share. Top ten major players are Roche Diagnostics, Siemens Healthcare(Erlangen, Germany), Abbott(Abbott Park, Illinois), Johnson and Johnson(New Jersey), Beckman Coulter(Massachusetts), Becton Dickinson(U.S.), bioMerieux (France), Bayer Diabetes(Germany), Sysmex (U.S.) and Bio-Rad(California). Key players such as Thermo Fisher Scientific, Inc., QIAGEN N.V., and ARKRAY, Inc. have established new manufacturing facilities and R&D units in China to grow IVD market.
The focus of this research report description was on various levels of analysis, industry, market shares, value chain, PESTEL analysis and company profiles which together comprise and augment about competitive landscape, emerging and high growth segments of in vitro diagnostic (molecular diagnostics & point of care testing), emerging technologies.
The report provides an in depth market analysis of the above mentioned segments across the following regions:
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
1. EXECUTIVE SUMMARY.
2. INTRODUCTION.
2.1. Key Take Aways.
2.2. Report Description.
2.3. Markets Covered.
2.4. Stakeholders.
2.5. Research Methodology.
2.5.1. Market Size Estimation.
2.5.2. Market Breakdown And Data Triangulation.
2.5.3. Key Data Points From Secondary Sources.
2.5.4. Key Data Points From Primary Sources.
2.5.5. Assumptions.
3. MARKET ANALYSIS.
3.1. Introduction.
3.2. Market Segmentation.
3.3. Factors Influencing Market.
3.3.1. Drivers And Opportunities.
3.3.1.1. Aged Cohort With Increased Incidence Of Chronic And Infectious Diseases And Implementation Of Minimal Invasive Technology.
3.3.1.2. Point-Of-Care Testing (Poct) And Its Technological Advancements.
3.3.1.3. Prevalence Of Personalized Medicine Approach.
3.3.1.4. Cost-Effectiveness.
3.3.1.5. Healthcare Awareness And Government Funding.
3.3.1.6. Extending Reach Of Molecular Diagnostics.
3.3.1.7. Commercial Trends For Development Of Condition-Specific Markers In Ivd Tests.
3.3.1.8. Biothreat Warfare Agents Posing An Opportunity.
3.3.2. Restraints And Threats.
3.3.2.1. Affordability Of Healthcare Diagnostics.
3.3.2.2. Intensified Competition.
3.3.2.3. Reimbursement Issues.
3.3.2.4. Stringent Regulatory Framework:.
3.3.2.5. Medical Device Excise Tax:.
3.3.3. Problem Areas.
3.3.3.1. Laboratory Automation For Increased Efficiency And Accurate Diagnosis:.
3.3.4. Winning Imperative.
3.3.4.1. Non-Proprietary System With Enhanced Functionalities.
3.4. Regulatory Affairs.
3.4.1. U.S..
3.4.2. Europe.
3.4.3. China.
3.4.4. India.
3.4.5. Japan.
3.5. Porter’S Five Force Analysis.
3.5.1. Threat Of New Entrants.
3.5.2. Threat Of Substitutes.
3.5.3. Rivalry Among Existing Competitors.
3.5.4. Bargaining Power Of Suppliers.
3.5.5. Bargaining Power Of Buyers.
3.6. Supply Chain Analysis.
3.7. Market Share Analysis By Major Players.
4. GLOBAL IVD MARKET, BY TECHNIQUE.
4.1. Introduction.
4.2. Immunology.
4.3. Hematology.
4.4. Clinical Chemistry.
4.5. Molecular Diagnostics.
4.6. Coagulation.
4.7. Microbiology.
4.8. Other Clinical Instruments.
5. GLOBAL IVD MARKET, BY PRODUCTS.
5.1. Introduction.
5.2. Reagents.
5.3. Instruments.
5.4. Services.
5.5. Data Management System Software/Hardware.
6. GLOBAL IVD MARKET, BY APPLICATION.
6.1. Introduction.
6.1. Infectious Diseases.
6.2. Diabetes.
6.3. Oncology.
6.4. Cardiology.
6.5. Nephrology.
6.6. Autoimmune Disease.
6.7. Sexually Transmitted Diseases.
6.7.1. Human Immunodeficiency Virus Infection.
6.8. Drug Testing.
6.9. Others.
7. GLOBAL IVD MARKET, BY END-USERS.
7.1. Introduction.
7.2. Hospitals.
7.3. Laboratory.
7.4. Patient Self-Testing.
7.5. Point Of Care Testing.
7.6. Academics.
7.7. Others.
8. REGIONAL MARKET ANALYSIS.
8.1. Introduction.
8.2. North America.
8.3. Europe.
8.4. Asia Pacific.
8.5. Rest Of The World.
9. COMPANY DEVELOPMENTS.
9.1. Introduction.
9.2. New Product Launch.
9.3. Agreements, Partnerships, Collaborations & Joint Ventures.
9.4. Mergers And Acquisitions.
9.5. Approvals.
9.6. Other Developments.
10. MAJOR PLAYER PROFILES.
10.1. Abbott Laboratories.
10.1.1. Overview.
10.1.2. Financials.
10.1.3. Product Portfolio.
10.1.4. Key Developments.
10.1.5. Business Strategy.
10.1.6. Swot Analysis.
10.2. Alere Inc..
10.2.1. Overview.
10.2.2. Financials.
10.2.3. Product Portfolio.
10.2.4. Key Developments.
10.2.5. Business Strategy.
10.2.6. Swot Analysis.
10.3. Bayer Ag.
10.3.1. Overview.
10.3.2. Financials.
10.3.3. Product Portfolio.
10.3.4. Key Developments.
10.3.5. Business Strategy.
10.3.6. Swot Analysis.
10.4. Becton, Dickinson And Company.
10.4.1. Overview.
10.4.2. Financials.
10.4.3. Product Portfolio.
10.4.4. Key Developments.
10.4.5. Business Strategy.
10.4.6. Swot Analysis.
10.5. Biomerieux.
10.5.1. Overview.
10.5.2. Financials.
10.5.3. Product Portfolio.
10.5.4. Key Developments.
10.5.5. Business Strategy.
10.5.6. Swot Analysis.
10.6. Bio-Rad Laboratories.
10.6.1. Overview.
10.6.2. Financials.
10.6.3. Product Portfolio.
10.6.4. Key Developments.
10.6.5. Business Strategy.
10.6.6. Swot Analysis.
10.7. Danaher Corporation.
10.7.1. Overview.
10.7.2. Financials.
10.7.3. Product Portfolio.
10.7.4. Key Developments.
10.7.5. Business Strategy.
10.7.6. Swot Analysis.
10.8. Johnson & Johnson.
10.8.1. Overview.
10.8.2. Financials.
10.8.3. Product Portfolio.
10.8.4. Key Developments.
10.8.5. Business Strategy.
10.8.6. Swot Analysis.
10.9. Roche Ltd..
10.9.1. Overview.
10.9.2. Financials.
10.9.3. Product Portfolio.
10.9.4. Key Developments.
10.9.5. Business Strategy.
10.9.6. Swot Analysis.
10.10. Siemens Ag.
10.10.1. Overview.
10.10.2. Financials.
10.10.3. Product Portfolio.
10.10.4. Key Developments.
10.10.5. Business Strategy.
10.10.6. Swot Analysis.
10.11. Sysmex Corporation.
10.11.1. Overview.
10.11.2. Financials.
10.11.3. Product Portfolio.
10.11.4. Key Developments.
10.11.5. Business Strategy.
10.11.6. Swot Analysis.
10.12. Thermo Fisher Scientific Inc..
10.12.1. Overview.
10.12.2. Financials.
10.12.3. Product Portfolio.
10.12.4. Key Developments.
10.12.5. Business Strategy.
10.12.6. Swot Analysis.
2. INTRODUCTION.
2.1. Key Take Aways.
2.2. Report Description.
2.3. Markets Covered.
2.4. Stakeholders.
2.5. Research Methodology.
2.5.1. Market Size Estimation.
2.5.2. Market Breakdown And Data Triangulation.
2.5.3. Key Data Points From Secondary Sources.
2.5.4. Key Data Points From Primary Sources.
2.5.5. Assumptions.
3. MARKET ANALYSIS.
3.1. Introduction.
3.2. Market Segmentation.
3.3. Factors Influencing Market.
3.3.1. Drivers And Opportunities.
3.3.1.1. Aged Cohort With Increased Incidence Of Chronic And Infectious Diseases And Implementation Of Minimal Invasive Technology.
3.3.1.2. Point-Of-Care Testing (Poct) And Its Technological Advancements.
3.3.1.3. Prevalence Of Personalized Medicine Approach.
3.3.1.4. Cost-Effectiveness.
3.3.1.5. Healthcare Awareness And Government Funding.
3.3.1.6. Extending Reach Of Molecular Diagnostics.
3.3.1.7. Commercial Trends For Development Of Condition-Specific Markers In Ivd Tests.
3.3.1.8. Biothreat Warfare Agents Posing An Opportunity.
3.3.2. Restraints And Threats.
3.3.2.1. Affordability Of Healthcare Diagnostics.
3.3.2.2. Intensified Competition.
3.3.2.3. Reimbursement Issues.
3.3.2.4. Stringent Regulatory Framework:.
3.3.2.5. Medical Device Excise Tax:.
3.3.3. Problem Areas.
3.3.3.1. Laboratory Automation For Increased Efficiency And Accurate Diagnosis:.
3.3.4. Winning Imperative.
3.3.4.1. Non-Proprietary System With Enhanced Functionalities.
3.4. Regulatory Affairs.
3.4.1. U.S..
3.4.2. Europe.
3.4.3. China.
3.4.4. India.
3.4.5. Japan.
3.5. Porter’S Five Force Analysis.
3.5.1. Threat Of New Entrants.
3.5.2. Threat Of Substitutes.
3.5.3. Rivalry Among Existing Competitors.
3.5.4. Bargaining Power Of Suppliers.
3.5.5. Bargaining Power Of Buyers.
3.6. Supply Chain Analysis.
3.7. Market Share Analysis By Major Players.
4. GLOBAL IVD MARKET, BY TECHNIQUE.
4.1. Introduction.
4.2. Immunology.
4.3. Hematology.
4.4. Clinical Chemistry.
4.5. Molecular Diagnostics.
4.6. Coagulation.
4.7. Microbiology.
4.8. Other Clinical Instruments.
5. GLOBAL IVD MARKET, BY PRODUCTS.
5.1. Introduction.
5.2. Reagents.
5.3. Instruments.
5.4. Services.
5.5. Data Management System Software/Hardware.
6. GLOBAL IVD MARKET, BY APPLICATION.
6.1. Introduction.
6.1. Infectious Diseases.
6.2. Diabetes.
6.3. Oncology.
6.4. Cardiology.
6.5. Nephrology.
6.6. Autoimmune Disease.
6.7. Sexually Transmitted Diseases.
6.7.1. Human Immunodeficiency Virus Infection.
6.8. Drug Testing.
6.9. Others.
7. GLOBAL IVD MARKET, BY END-USERS.
7.1. Introduction.
7.2. Hospitals.
7.3. Laboratory.
7.4. Patient Self-Testing.
7.5. Point Of Care Testing.
7.6. Academics.
7.7. Others.
8. REGIONAL MARKET ANALYSIS.
8.1. Introduction.
8.2. North America.
8.3. Europe.
8.4. Asia Pacific.
8.5. Rest Of The World.
9. COMPANY DEVELOPMENTS.
9.1. Introduction.
9.2. New Product Launch.
9.3. Agreements, Partnerships, Collaborations & Joint Ventures.
9.4. Mergers And Acquisitions.
9.5. Approvals.
9.6. Other Developments.
10. MAJOR PLAYER PROFILES.
10.1. Abbott Laboratories.
10.1.1. Overview.
10.1.2. Financials.
10.1.3. Product Portfolio.
10.1.4. Key Developments.
10.1.5. Business Strategy.
10.1.6. Swot Analysis.
10.2. Alere Inc..
10.2.1. Overview.
10.2.2. Financials.
10.2.3. Product Portfolio.
10.2.4. Key Developments.
10.2.5. Business Strategy.
10.2.6. Swot Analysis.
10.3. Bayer Ag.
10.3.1. Overview.
10.3.2. Financials.
10.3.3. Product Portfolio.
10.3.4. Key Developments.
10.3.5. Business Strategy.
10.3.6. Swot Analysis.
10.4. Becton, Dickinson And Company.
10.4.1. Overview.
10.4.2. Financials.
10.4.3. Product Portfolio.
10.4.4. Key Developments.
10.4.5. Business Strategy.
10.4.6. Swot Analysis.
10.5. Biomerieux.
10.5.1. Overview.
10.5.2. Financials.
10.5.3. Product Portfolio.
10.5.4. Key Developments.
10.5.5. Business Strategy.
10.5.6. Swot Analysis.
10.6. Bio-Rad Laboratories.
10.6.1. Overview.
10.6.2. Financials.
10.6.3. Product Portfolio.
10.6.4. Key Developments.
10.6.5. Business Strategy.
10.6.6. Swot Analysis.
10.7. Danaher Corporation.
10.7.1. Overview.
10.7.2. Financials.
10.7.3. Product Portfolio.
10.7.4. Key Developments.
10.7.5. Business Strategy.
10.7.6. Swot Analysis.
10.8. Johnson & Johnson.
10.8.1. Overview.
10.8.2. Financials.
10.8.3. Product Portfolio.
10.8.4. Key Developments.
10.8.5. Business Strategy.
10.8.6. Swot Analysis.
10.9. Roche Ltd..
10.9.1. Overview.
10.9.2. Financials.
10.9.3. Product Portfolio.
10.9.4. Key Developments.
10.9.5. Business Strategy.
10.9.6. Swot Analysis.
10.10. Siemens Ag.
10.10.1. Overview.
10.10.2. Financials.
10.10.3. Product Portfolio.
10.10.4. Key Developments.
10.10.5. Business Strategy.
10.10.6. Swot Analysis.
10.11. Sysmex Corporation.
10.11.1. Overview.
10.11.2. Financials.
10.11.3. Product Portfolio.
10.11.4. Key Developments.
10.11.5. Business Strategy.
10.11.6. Swot Analysis.
10.12. Thermo Fisher Scientific Inc..
10.12.1. Overview.
10.12.2. Financials.
10.12.3. Product Portfolio.
10.12.4. Key Developments.
10.12.5. Business Strategy.
10.12.6. Swot Analysis.
LIST OF TABLES:
Table 1. Ivd Instruments & Reagents Global Market Revenue, By Geography, (2012-2020) ($Bn).
Table 2. Ivd Instruments & Reagents Global Market Revenue, By Technique, (2012-2020) ($Bn).
Table 3. Ivd Instruments & Reagents Global Market Revenue, By Technique, (2012-2020) ($Bn).
Table 4. Ivd Instruments & Reagents Immunology Market Revenue, By Geography, (2012-2020) ($Bn).
Table 5. Ivd Instruments & Reagents Hematology Market Revenue, By Geography, (2012-2020) ($Bn).
Table 6. Ivd Instruments & Reagents Clinical Chemistry Market Revenue, By Geography, (2012-2020) ($Bn).
Table 7. Ivd Instruments & Reagents Molecular Diagnostics Market Revenue, By Geography, (2012-2020) ($Bn).
Table 8. Ivd Instruments & Reagents Coagulation Market Revenue, By Geography, (2012-2020) ($Bn).
Table 9. Ivd Instruments & Reagents Microbiology Market Revenue, By Geography, (2012-2020) ($Bn).
Table 10. Ivd Instruments & Reagents Other Clinical Instruments Market Revenue, By Geography, (2012-2020) ($Bn).
Table 11. Ivd Instruments & Reagents Global Market Revenue, By Products (2012-2020) ($Bn).
Table 12. Ivd Reagents Market Revenue, By Geography, (2012-2020) ($Bn).
Table 13. Ivd Instruments Market Revenue, By Geography, (2012-2020) ($Bn).
Table 14. Ivd Services Market Revenue, By Geography, (2012-2020) ($Bn).
Table 15. Ivd Data Management System Software/Hardware Market Revenue, By Geography, (2012-2020) ($Bn).
Table 16. Ivd Instruments & Reagents Global Market Revenue, By Applications (2012-2020) ($Bn).
Table 17. Ivd Infectious Diseases Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 18. Ivd Diabetes Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 19. Ivd Oncology/Cancer Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 20. Ivd Cardiology Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 21. Ivd Nephrology Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 22. Ivd Autoimmune Diseases Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 23. Ivd Std Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 24. Ivd Drug Testing Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 25. Ivd Other Applications Market Revenue, By Geography, (2012-2020) ($Bn).
Table 26. Ivd Instruments & Reagents Global Market Revenue, By End Users (2012-2020) ($Bn).
Table 27. Ivd Hospital End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 28. Ivd Laboratory End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 29. Ivd Patient Self-Testing End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 30. Ivd Point Of Care Testing End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 31. Ivd Academics End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 32. Ivd Other End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 33. Global Ivd Market, By Geography, 2013 - 2020 ($Bn).
Table 34. North American Ivd Instruments & Reagents Market Revenue, By Technique, (2012-2020) ($Bn).
Table 35. North American Ivd Instruments & Reagents Market Revenue, By Products (2012-2020) ($Bn).
Table 36. North American Ivd Instruments & Reagents Market Revenue, By Applications (2012-2020) ($Bn).
Table 37. North American Ivd Instruments & Reagents Market Revenue, By End Users (2012-2020) ($Bn).
Table 38. European Ivd Instruments & Reagents Market Revenue, By Technique, (2012-2020) ($Bn).
Table 39. European Ivd Instruments & Reagents Market Revenue, By Products (2012-2020) ($Bn).
Table 40. European Ivd Instruments & Reagents Market Revenue, By Applications (2012-2020) ($Bn).
Table 41. European Ivd Instruments & Reagents Market Revenue, By End Users (2012-2020) ($Bn).
Table 42. Asia-Pacific Ivd Instruments & Reagents Market Revenue, By Technique, (2012-2020) ($Bn).
Table 43. Asia-Pacific Ivd Instruments & Reagents Global Market Revenue, By Products (2012-2020) ($Bn).
Table 44. Asia-Pacific Ivd Instruments & Reagents Market Revenue, By Applications (2012-2020) ($Bn).
Table 45. Asia-Pacific Ivd Instruments & Reagents Market Revenue, By End Users (2012-2020) ($Bn).
Table 46. Row Ivd Instruments & Reagents Market Revenue, By Technique, (2012-2020) ($Bn).
Table 47. Row Ivd Instruments & Reagents Market Revenue, By Products (2012-2020) ($Bn).
Table 48. Row Ivd Instruments & Reagents Market Revenue, By Applications (2012-2020) ($Bn).
Table 49. Row Ivd Instruments & Reagents Market Revenue, By End Users (2012-2020) ($Bn).
Table 50. New Product Launches (2011-2014).
Table 51. Agreements, Partnerships, Collaborations, & Joint Ventures (2011-2014).
Table 52. Mergers And Acquisitions (2011-2014).
Table 53. Approvals, (2012-2014).
Table 54. Other Developments (2013-2014).
Table 55. Abbott Laboratories: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 56. Abbott Laboratories: Total Revenue, By Segments (2011-2013) ($Bn).
Table 57. Abbott Laboratories: Total Revenue, By Geography (2011-2013) ($Bn).
Table 58. Alere Inc: Total Revenue And R&D Expenses, (2011-13) ($Mn).
Table 59. Alere Inc.: Diagnostic Revenues, By Segments (2011-2013) ($Mn).
Table 60. Alere Inc.: Professional Diagnostics Revenue, By Segments, 2011-2013 ($Mn).
Table 61. Alere Inc.: Total Revenue, By Geography 2011-13 ($Mn).
Table 62. Bayer Ag: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 63. Bayer Ag: Total Revenue, By Segments (2011-2013) ($Bn).
Table 64. Bayer Ag: Total Revenue, By Geography (2011-2013) ($Bn).
Table 65. Becton, Dickinson And Company: Total Revenue And R&D Expenses (2011-2013) ($Mn).
Table 66. Becton, Dickinson And Company: Diagnostic Revenues, By Segments (2011-2013) ($ Mn).
Table 67. Becton, Dickinson And Company: Total Revenue, By Geography (2011-2013) ($ Mn).
Table 68. Biomerieux: Total Revenue And Operating Expenses (2011-2013) ($Bn).
Table 69. Biomerieux: Total Revenue, By Segments (2011-2013) ($Bn).
Table 70. Biomerieux: Total Revenue, By Geography (2011-2013) ($Bn).
Table 71. Bio-Rad Laboratories: Total Revenue And R&D Expenses (2011-2013) ($Mn).
Table 72. Bio-Rad Laboratories: Total Revenue, By Segments (2011-2013) ($Mn).
Table 73. Bio-Rad Laboratories: Total Revenue, By Geography (2011-2013) ($Mn).
Table 74. Danaher Corporation: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 75. Danaher Corporation: Total Revenue, By Segments (2011-2013) ($Bn).
Table 76. Danaher Corporation: Total Revenue, By Geography (2011-2013) ($Bn).
Table 77. Johnson & Johnson: Total Revenue And R&D Expenses 2011-2013($ Bn). .
Table 78. Johnson & Johnson: Total Revenue, By Segments (2011-2013) ($Bn).
Table 79. Johnson & Johnson: Medical Devices And Diagnostics Revenue, By Segments(2011-2013) ($Bn).
Table 80. Johnson & Johnson: Geographical Revenue, By Region (2011-2013) ($Bn).
Table 81. Roche Ltd.: Total Revenue And R&D Expenses, (2011-2013) ($Bn).
Table 82. Roche Ltd.: Total Revenue, By Segments, (2011-2013) ($Bn).
Table 83. Roche Ltd.: Diagnostics Revenue, By Segments, (2011-2013) ($Bn).
Table 84. Roche Ltd.: Total Revenue, By Geography (2011-2013) ($Bn).
Table 85. Siemens Ag: Total Revenue And R&D Expenses, (2011-2013) ($Bn).
Table 86. Siemens Ag: Total Revenue, By Segments, (2011-13) ($Bn).
Table 87. Siemens Ag: Total Revenue, By Geography (2011-2013) ($Bn).
Table 88. Siemens Ag: Healthcare Revenue, By Geography (2011-2013) ($Bn).
Table 89. Sysmex Corporation: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 90. Sysmex Corporation: Total Revenue, By Segments (2011-2013) ($Bn).
Table 91. Sysmex Corporation: Total Revenue, By Diagostics (2011-2013) ($Bn).
Table 92. Sysmex Corporation: Total Revenue, By Geography (2011-2013) ($Bn).
Table 93. Thermo Fisher Scientific Inc.: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 94. Thermo Fisher Scientific Inc.: Total Revenue, By Segments (2011-2013) ($Bn).
Table 95. Thermo Fisher Scientific Inc.: Total Revenue, By Geography (2011-2013) ($Bn).
Table 1. Ivd Instruments & Reagents Global Market Revenue, By Geography, (2012-2020) ($Bn).
Table 2. Ivd Instruments & Reagents Global Market Revenue, By Technique, (2012-2020) ($Bn).
Table 3. Ivd Instruments & Reagents Global Market Revenue, By Technique, (2012-2020) ($Bn).
Table 4. Ivd Instruments & Reagents Immunology Market Revenue, By Geography, (2012-2020) ($Bn).
Table 5. Ivd Instruments & Reagents Hematology Market Revenue, By Geography, (2012-2020) ($Bn).
Table 6. Ivd Instruments & Reagents Clinical Chemistry Market Revenue, By Geography, (2012-2020) ($Bn).
Table 7. Ivd Instruments & Reagents Molecular Diagnostics Market Revenue, By Geography, (2012-2020) ($Bn).
Table 8. Ivd Instruments & Reagents Coagulation Market Revenue, By Geography, (2012-2020) ($Bn).
Table 9. Ivd Instruments & Reagents Microbiology Market Revenue, By Geography, (2012-2020) ($Bn).
Table 10. Ivd Instruments & Reagents Other Clinical Instruments Market Revenue, By Geography, (2012-2020) ($Bn).
Table 11. Ivd Instruments & Reagents Global Market Revenue, By Products (2012-2020) ($Bn).
Table 12. Ivd Reagents Market Revenue, By Geography, (2012-2020) ($Bn).
Table 13. Ivd Instruments Market Revenue, By Geography, (2012-2020) ($Bn).
Table 14. Ivd Services Market Revenue, By Geography, (2012-2020) ($Bn).
Table 15. Ivd Data Management System Software/Hardware Market Revenue, By Geography, (2012-2020) ($Bn).
Table 16. Ivd Instruments & Reagents Global Market Revenue, By Applications (2012-2020) ($Bn).
Table 17. Ivd Infectious Diseases Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 18. Ivd Diabetes Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 19. Ivd Oncology/Cancer Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 20. Ivd Cardiology Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 21. Ivd Nephrology Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 22. Ivd Autoimmune Diseases Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 23. Ivd Std Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 24. Ivd Drug Testing Application Market Revenue, By Geography, (2012-2020) ($Bn).
Table 25. Ivd Other Applications Market Revenue, By Geography, (2012-2020) ($Bn).
Table 26. Ivd Instruments & Reagents Global Market Revenue, By End Users (2012-2020) ($Bn).
Table 27. Ivd Hospital End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 28. Ivd Laboratory End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 29. Ivd Patient Self-Testing End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 30. Ivd Point Of Care Testing End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 31. Ivd Academics End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 32. Ivd Other End Users Market Revenue, By Geography, (2012-2020) ($Bn).
Table 33. Global Ivd Market, By Geography, 2013 - 2020 ($Bn).
Table 34. North American Ivd Instruments & Reagents Market Revenue, By Technique, (2012-2020) ($Bn).
Table 35. North American Ivd Instruments & Reagents Market Revenue, By Products (2012-2020) ($Bn).
Table 36. North American Ivd Instruments & Reagents Market Revenue, By Applications (2012-2020) ($Bn).
Table 37. North American Ivd Instruments & Reagents Market Revenue, By End Users (2012-2020) ($Bn).
Table 38. European Ivd Instruments & Reagents Market Revenue, By Technique, (2012-2020) ($Bn).
Table 39. European Ivd Instruments & Reagents Market Revenue, By Products (2012-2020) ($Bn).
Table 40. European Ivd Instruments & Reagents Market Revenue, By Applications (2012-2020) ($Bn).
Table 41. European Ivd Instruments & Reagents Market Revenue, By End Users (2012-2020) ($Bn).
Table 42. Asia-Pacific Ivd Instruments & Reagents Market Revenue, By Technique, (2012-2020) ($Bn).
Table 43. Asia-Pacific Ivd Instruments & Reagents Global Market Revenue, By Products (2012-2020) ($Bn).
Table 44. Asia-Pacific Ivd Instruments & Reagents Market Revenue, By Applications (2012-2020) ($Bn).
Table 45. Asia-Pacific Ivd Instruments & Reagents Market Revenue, By End Users (2012-2020) ($Bn).
Table 46. Row Ivd Instruments & Reagents Market Revenue, By Technique, (2012-2020) ($Bn).
Table 47. Row Ivd Instruments & Reagents Market Revenue, By Products (2012-2020) ($Bn).
Table 48. Row Ivd Instruments & Reagents Market Revenue, By Applications (2012-2020) ($Bn).
Table 49. Row Ivd Instruments & Reagents Market Revenue, By End Users (2012-2020) ($Bn).
Table 50. New Product Launches (2011-2014).
Table 51. Agreements, Partnerships, Collaborations, & Joint Ventures (2011-2014).
Table 52. Mergers And Acquisitions (2011-2014).
Table 53. Approvals, (2012-2014).
Table 54. Other Developments (2013-2014).
Table 55. Abbott Laboratories: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 56. Abbott Laboratories: Total Revenue, By Segments (2011-2013) ($Bn).
Table 57. Abbott Laboratories: Total Revenue, By Geography (2011-2013) ($Bn).
Table 58. Alere Inc: Total Revenue And R&D Expenses, (2011-13) ($Mn).
Table 59. Alere Inc.: Diagnostic Revenues, By Segments (2011-2013) ($Mn).
Table 60. Alere Inc.: Professional Diagnostics Revenue, By Segments, 2011-2013 ($Mn).
Table 61. Alere Inc.: Total Revenue, By Geography 2011-13 ($Mn).
Table 62. Bayer Ag: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 63. Bayer Ag: Total Revenue, By Segments (2011-2013) ($Bn).
Table 64. Bayer Ag: Total Revenue, By Geography (2011-2013) ($Bn).
Table 65. Becton, Dickinson And Company: Total Revenue And R&D Expenses (2011-2013) ($Mn).
Table 66. Becton, Dickinson And Company: Diagnostic Revenues, By Segments (2011-2013) ($ Mn).
Table 67. Becton, Dickinson And Company: Total Revenue, By Geography (2011-2013) ($ Mn).
Table 68. Biomerieux: Total Revenue And Operating Expenses (2011-2013) ($Bn).
Table 69. Biomerieux: Total Revenue, By Segments (2011-2013) ($Bn).
Table 70. Biomerieux: Total Revenue, By Geography (2011-2013) ($Bn).
Table 71. Bio-Rad Laboratories: Total Revenue And R&D Expenses (2011-2013) ($Mn).
Table 72. Bio-Rad Laboratories: Total Revenue, By Segments (2011-2013) ($Mn).
Table 73. Bio-Rad Laboratories: Total Revenue, By Geography (2011-2013) ($Mn).
Table 74. Danaher Corporation: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 75. Danaher Corporation: Total Revenue, By Segments (2011-2013) ($Bn).
Table 76. Danaher Corporation: Total Revenue, By Geography (2011-2013) ($Bn).
Table 77. Johnson & Johnson: Total Revenue And R&D Expenses 2011-2013($ Bn). .
Table 78. Johnson & Johnson: Total Revenue, By Segments (2011-2013) ($Bn).
Table 79. Johnson & Johnson: Medical Devices And Diagnostics Revenue, By Segments(2011-2013) ($Bn).
Table 80. Johnson & Johnson: Geographical Revenue, By Region (2011-2013) ($Bn).
Table 81. Roche Ltd.: Total Revenue And R&D Expenses, (2011-2013) ($Bn).
Table 82. Roche Ltd.: Total Revenue, By Segments, (2011-2013) ($Bn).
Table 83. Roche Ltd.: Diagnostics Revenue, By Segments, (2011-2013) ($Bn).
Table 84. Roche Ltd.: Total Revenue, By Geography (2011-2013) ($Bn).
Table 85. Siemens Ag: Total Revenue And R&D Expenses, (2011-2013) ($Bn).
Table 86. Siemens Ag: Total Revenue, By Segments, (2011-13) ($Bn).
Table 87. Siemens Ag: Total Revenue, By Geography (2011-2013) ($Bn).
Table 88. Siemens Ag: Healthcare Revenue, By Geography (2011-2013) ($Bn).
Table 89. Sysmex Corporation: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 90. Sysmex Corporation: Total Revenue, By Segments (2011-2013) ($Bn).
Table 91. Sysmex Corporation: Total Revenue, By Diagostics (2011-2013) ($Bn).
Table 92. Sysmex Corporation: Total Revenue, By Geography (2011-2013) ($Bn).
Table 93. Thermo Fisher Scientific Inc.: Total Revenue And R&D Expenses (2011-2013) ($Bn).
Table 94. Thermo Fisher Scientific Inc.: Total Revenue, By Segments (2011-2013) ($Bn).
Table 95. Thermo Fisher Scientific Inc.: Total Revenue, By Geography (2011-2013) ($Bn).
LIST OF FIGURES:
Figure 1. Executive Summary: Global Ivd Market Share, By Geography (2013).
Figure 2. Research Methodology: In-Vitro Diagnostics Market.
Figure 3. Ivd Market: Top-Down And Bottom-Up Approach.
Figure 4. Ivd Market: Forecasting Model.
Figure 5. Ivd Market: Market Breakdown & Data Triangulation.
Figure 6. Ivd Market: Market Segmentation.
Figure 7. Market Dynamics.
Figure 8. Ivd Market: Porter’S Analysis.
Figure 9. Ivd Market: Supply Chain Analysis.
Figure 10. Global In-Vitro Diagnostics Market Share Analysis, By Key Player, 2012.
Figure 11. Key Growth Strategies, (2011-2014).
Figure 12. Swot: Abbott Laboratories Inc.
Figure 13. Swot: Alere Inc..
Figure 14. Swot: Alere Inc.
Figure 15. Swot: Becton, Dickinson And Company.
Figure 16. Swot: Biomerieux.
Figure 17. Swot: Biorad Laboratories, Inc..
Figure 18. Swot: Danaher Corporation.
Figure 19. Swot: Johnson & Johnson.
Figure 20. Swot: Roche Diagnostics.
Figure 21. Swot: Siemens Healthcare.
Figure 22. Swot: Sysmex Corporation.
Figure 23. Swot: Thermo Fischer Scientific.
Figure 1. Executive Summary: Global Ivd Market Share, By Geography (2013).
Figure 2. Research Methodology: In-Vitro Diagnostics Market.
Figure 3. Ivd Market: Top-Down And Bottom-Up Approach.
Figure 4. Ivd Market: Forecasting Model.
Figure 5. Ivd Market: Market Breakdown & Data Triangulation.
Figure 6. Ivd Market: Market Segmentation.
Figure 7. Market Dynamics.
Figure 8. Ivd Market: Porter’S Analysis.
Figure 9. Ivd Market: Supply Chain Analysis.
Figure 10. Global In-Vitro Diagnostics Market Share Analysis, By Key Player, 2012.
Figure 11. Key Growth Strategies, (2011-2014).
Figure 12. Swot: Abbott Laboratories Inc.
Figure 13. Swot: Alere Inc..
Figure 14. Swot: Alere Inc.
Figure 15. Swot: Becton, Dickinson And Company.
Figure 16. Swot: Biomerieux.
Figure 17. Swot: Biorad Laboratories, Inc..
Figure 18. Swot: Danaher Corporation.
Figure 19. Swot: Johnson & Johnson.
Figure 20. Swot: Roche Diagnostics.
Figure 21. Swot: Siemens Healthcare.
Figure 22. Swot: Sysmex Corporation.
Figure 23. Swot: Thermo Fischer Scientific.
